Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 455-460

  Kaira, Kyoichi ^a   Takise, Atsushi ^a   Minato, Koichi ^b   Iwasaki, Yasuki ^c   Ishihara, Shinichi ^c   Takei, Yoshikazu ^c   Tsuchiya, Satoshi ^c   Saito, Ryusei ^c   Sato, Koji ^d   Mori, Masatomo ^e  

^a MAEBASHI RED CROSS HOSPITAL   (Japan)

^b Gunma Cancer Center   (Japan)

^c National Sanatorium Nishigunma Hospital   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Non small cell lung cancer; Phase II study; Weekly administration

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; DEXAMETHASONE; DOCETAXEL; GEFITINIB; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TAXOIDS;

EID: 20144388692     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00013     Document Type: Article

References (28)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899-909.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92-98.
3. Denis JN, Correa A, Greene AE. An improved synthesis of the Taxol side chain and of RP56976. J Org Chem 1990; 55:1957-1959.
4. Kunitoh H, Watanabe K, Onoshi T, Furse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer. J Clin Oncol 1996; 14:1649-1655.
5. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12:1238-1244.
6. Francis PA, Rigas JR, Kris MG, Orazem JP, Woolley KJ, Heelan RT, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12:1232-1237.
7. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13:645-651.
8. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, Levitan N, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
9. Kelland LR, Abel G. Comparative cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1995; 30:444-450.
10. Fossella BF, Pereira JR, Belani CP, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003; 21:3016-3024.
11. Hainsworth JD, Burris 3rd HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16:2164-2168.
12. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakou E, Fountzilas G, Rammou D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10:701-706.
13. Greco FA. Docetaxel (Taxotere) administrated in weekly schedules. Semin Oncol 1999; 26(suppl 11):28-31.
14. Sato K, Tsuchiya S, Minato K, Takei Y, Watanabe S, Saitoh R, et al. A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer. Lung Cancer 2001; 33:69-73.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Ass 1985; 53:457-481.
17. Georgoulias V, Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, et al. Front-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998; 9:331-334.
18. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 1998; 16:1948-1953.
19. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 1998; 34:2032-2036.
20. Belani CP, Bonomi P, Dobbs TW, DeVore RF, Ettinger DS, Jett J, et al. Docetaxel and cisplatin in patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer 1999; 1: 144-150.
21. Okamoto H, Watanabe K, Segawa Y, Ichinose Y, Yokoyama A, Yoneda S, et al. Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer. Int J Clin Oncol 2000; 5:316-322.
22. Hainsworth JD, Burris HA III, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89:328-333.
23. Niho S, Ohe Y, Kakinuma R, Kubota K, Matsumoto T, Nishiwaki Y, et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 2002; 35:209-214.
24. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 1986; 4:1037-1043.
25. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1986; 4:1780-1786.
26. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11:873-878.
27. Ohe Y, Niho S, Kakinuma K, Kubota K, Ohmatsu K, Goto H, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004; 15:45-50.
28. Tsunoda T, Koizumi T, Hayasaka M, Hirai K, Koyama S, Takabayashi Y, et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2004; 54:173-177.